Results 231 to 240 of about 19,107 (290)

Darier disease is associated with neurodegenerative disorders and epilepsy. [PDF]

open access: yesSci Rep
Curman P   +5 more
europepmc   +1 more source

BMI and Breast Subcutaneous Fat

open access: yesJournal of Ultrasound in Medicine, EarlyView.
Objectives Obesity is closely associated with the occurrence and progression of breast cancer. While body mass index (BMI) is widely used to diagnose obesity, it has certain limitations. Subcutaneous fat thickness (SFT) also serves as an indicator of body composition. However, studies on breast SFT are scarce.
Shiyu Wang   +5 more
wiley   +1 more source

Circulating miR-206, miR-181b, and miR-21 as promising biomarkers in hypothyroidism and their relationship to related hyperlipidemia and hepatic steatosis [PDF]

open access: gold
Asmaa Mohammed   +8 more
openalex   +1 more source

Pre‐ and Post‐Interventional Hemodynamic Characterization of the Femoropopliteal Artery Using Vector Flow Imaging in Peripheral Arterial Occlusive Disease

open access: yesJournal of Ultrasound in Medicine, EarlyView.
Objectives The femoropopliteal (FP) artery is the most frequently revascularized segment in peripheral artery disease (PAD), followed by the iliac segment. Wall shear stress (WSS) is a key local factor implicated in both atherosclerotic plaque formation and restenosis after angioplasty.
Jan Lukas Prüser   +5 more
wiley   +1 more source

Effects of Intravenous Laser Irradiation of Blood on Metabolic Markers in Patients With Hyperlipidemia: A Retrospective Pilot Study. [PDF]

open access: yesIn Vivo
Huang CY   +10 more
europepmc   +1 more source

Retardation and arrest of progression or regression of coronary artery disease: A review [PDF]

open access: yes, 1993
Deckers, J.W. (Jaap)   +4 more
core   +1 more source

Safety of Baricitinib for the Treatment of Atopic Dermatitis in Adults Over a Median of 1.6 and up to 4.6 Years Treatment: Final Integrated Analysis of Eight Clinical Trials

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Baricitinib is a selective Janus kinase (JAK)1/JAK2 inhibitor approved in more than 70 countries for the treatment of moderate‐to‐severe atopic dermatitis (AD) in adults, and in over 30 countries for adolescents and children from age 2 years with moderate‐to‐severe AD, who are candidates for systemic therapy.
Antonio Costanzo   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy